[
  {
    "ts": null,
    "headline": "Why Pfizer Stock Topped the Market on Tuesday",
    "summary": "On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer (NYSE: PFE).  On Tuesday, Pfizer's stock closed the day 1.5% higher, providing a pleasant contrast to the S&P 500 index's 0.2% dip.  Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug danuglipron.",
    "url": "https://finnhub.io/api/news?id=281c34d23d89ee447a362a70e2115469d03a09b8d4261f4a5b94bacbc36a2018",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744757588,
      "headline": "Why Pfizer Stock Topped the Market on Tuesday",
      "id": 133932830,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer (NYSE: PFE).  On Tuesday, Pfizer's stock closed the day 1.5% higher, providing a pleasant contrast to the S&P 500 index's 0.2% dip.  Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug danuglipron.",
      "url": "https://finnhub.io/api/news?id=281c34d23d89ee447a362a70e2115469d03a09b8d4261f4a5b94bacbc36a2018"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Value Select ETF Q1 2025 Commentary",
    "summary": "Parnassus Value Select ETF Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=2e31897592ea1dc508c320a8c41d17a62678f4ebcf905c5bf8468843de7fae7b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744753800,
      "headline": "Parnassus Value Select ETF Q1 2025 Commentary",
      "id": 133929990,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2e31897592ea1dc508c320a8c41d17a62678f4ebcf905c5bf8468843de7fae7b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Halts Obesity Pill Development Amid Safety Concerns",
    "summary": "PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.",
    "url": "https://finnhub.io/api/news?id=3331affb6c0b2bf193e2d253ab1303d26d95a032425f678a2e113d4054063d46",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744736220,
      "headline": "Pfizer Halts Obesity Pill Development Amid Safety Concerns",
      "id": 133927930,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.",
      "url": "https://finnhub.io/api/news?id=3331affb6c0b2bf193e2d253ab1303d26d95a032425f678a2e113d4054063d46"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=0abdf052a2392c2bee3af4cdfcb5092521a31af33bf112bec903b96ebaad399e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744734960,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 133948126,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=0abdf052a2392c2bee3af4cdfcb5092521a31af33bf112bec903b96ebaad399e"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market",
    "summary": "Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing risks remain. Click to know why VKTX is a Buy.",
    "url": "https://finnhub.io/api/news?id=f66e70cb2ce25d77f2724f8f6197654f1de5fe206e0af337fb60130dcbccc506",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744734098,
      "headline": "Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market",
      "id": 133928742,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304192083/image_1304192083.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing risks remain. Click to know why VKTX is a Buy.",
      "url": "https://finnhub.io/api/news?id=f66e70cb2ce25d77f2724f8f6197654f1de5fe206e0af337fb60130dcbccc506"
    }
  },
  {
    "ts": null,
    "headline": "BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged",
    "summary": "BofA analyst Tim Anderson notes Pfizer (PFE) announced danuglipron, an oral GLP-1 obesity, is being discontinued, following a case of liver injury seen in the phase 1 study. The firm points out that it has argued that this program has received almost too much attention – not because obesity isn’t important, but because this was only phase 1 data. Without danuglipron, Pfizer’s obesity pipeline now consists of a GIP receptor antagonist in phase 2 and a phase 1 oral GLP-1 in T2D with Nxera Pharma.",
    "url": "https://finnhub.io/api/news?id=104b5b341e39b49c6fdb1c837e60999d74cd689e0833c85975e717a89f2879bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744729532,
      "headline": "BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged",
      "id": 133922260,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BofA analyst Tim Anderson notes Pfizer (PFE) announced danuglipron, an oral GLP-1 obesity, is being discontinued, following a case of liver injury seen in the phase 1 study. The firm points out that it has argued that this program has received almost too much attention – not because obesity isn’t important, but because this was only phase 1 data. Without danuglipron, Pfizer’s obesity pipeline now consists of a GIP receptor antagonist in phase 2 and a phase 1 oral GLP-1 in T2D with Nxera Pharma.",
      "url": "https://finnhub.io/api/news?id=104b5b341e39b49c6fdb1c837e60999d74cd689e0833c85975e717a89f2879bb"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes",
    "summary": "Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX stock prospects.",
    "url": "https://finnhub.io/api/news?id=c30e1831f90d0e661f7f3fa680dba6ac78b39405ea2acc71e300a7cb47024298",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744727870,
      "headline": "Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes",
      "id": 133928198,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196950234/image_2196950234.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX stock prospects.",
      "url": "https://finnhub.io/api/news?id=c30e1831f90d0e661f7f3fa680dba6ac78b39405ea2acc71e300a7cb47024298"
    }
  },
  {
    "ts": null,
    "headline": "Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill",
    "summary": "Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts “limited reaction” in Pfizer’s shares following the news, JPMorgan tells investors that the decision is “mostly a positive” for Structure and Viking, both developing drugs in the",
    "url": "https://finnhub.io/api/news?id=73010c01a9588a7879ce392276d2f3d43e16b84d650a5442faec5fb1ec7d0cea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744727725,
      "headline": "Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill",
      "id": 133922054,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts “limited reaction” in Pfizer’s shares following the news, JPMorgan tells investors that the decision is “mostly a positive” for Structure and Viking, both developing drugs in the",
      "url": "https://finnhub.io/api/news?id=73010c01a9588a7879ce392276d2f3d43e16b84d650a5442faec5fb1ec7d0cea"
    }
  },
  {
    "ts": null,
    "headline": "NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback",
    "summary": "Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.",
    "url": "https://finnhub.io/api/news?id=54b748667207425b21b7ae1daf566df6e213627eb85f4a28aee70275a3aaa22a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744725600,
      "headline": "NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback",
      "id": 133922055,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.",
      "url": "https://finnhub.io/api/news?id=54b748667207425b21b7ae1daf566df6e213627eb85f4a28aee70275a3aaa22a"
    }
  },
  {
    "ts": null,
    "headline": "Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight Loss Pill?",
    "summary": "Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be.  On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 candidate for weight management.  Pfizer's stock price is way down, but the quarterly dividend it pays has risen for 16 consecutive years.",
    "url": "https://finnhub.io/api/news?id=5dbadd427fd5fa08ca52e9c4b449b2de5d352d11e6e71824879788d2f1d800df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744717140,
      "headline": "Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight Loss Pill?",
      "id": 133922263,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be.  On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 candidate for weight management.  Pfizer's stock price is way down, but the quarterly dividend it pays has risen for 16 consecutive years.",
      "url": "https://finnhub.io/api/news?id=5dbadd427fd5fa08ca52e9c4b449b2de5d352d11e6e71824879788d2f1d800df"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves",
    "summary": "Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves",
    "url": "https://finnhub.io/api/news?id=f25f4c39a585d24493d2a420885960c433e9542707a4c81432b13092d254ab72",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744713792,
      "headline": "Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves",
      "id": 133921555,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f25f4c39a585d24493d2a420885960c433e9542707a4c81432b13092d254ab72"
    }
  },
  {
    "ts": null,
    "headline": "The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now",
    "summary": "The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now",
    "url": "https://finnhub.io/api/news?id=6ae35fbfb7ca53ecc3a82a061c36a7b6c136d4c86e798243b80edcfff925bd80",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744708171,
      "headline": "The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now",
      "id": 133921057,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6ae35fbfb7ca53ecc3a82a061c36a7b6c136d4c86e798243b80edcfff925bd80"
    }
  },
  {
    "ts": null,
    "headline": "Why Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday?",
    "summary": "We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other biotech stocks that dominate Monday’s top gainers. The stock market kicked off the shortened trading week on a positive note, with Wall Street’s major […]",
    "url": "https://finnhub.io/api/news?id=0e5e7299621a1d59e6a50f777a9a707987365d1948c7ec3a3d92fd3e0dce74d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744692028,
      "headline": "Why Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday?",
      "id": 133917845,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other biotech stocks that dominate Monday’s top gainers. The stock market kicked off the shortened trading week on a positive note, with Wall Street’s major […]",
      "url": "https://finnhub.io/api/news?id=0e5e7299621a1d59e6a50f777a9a707987365d1948c7ec3a3d92fd3e0dce74d7"
    }
  },
  {
    "ts": null,
    "headline": "Trump Initiates Chips and Drug Probes Ahead of More Tariffs",
    "summary": "(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergHow Did This Suburb Figure Out Mass Transit?The Secret Formula for Faster TrainsEven Oslo Has an Air Quality ProblemNYC Tourist Helicopter Crashes in Hudson River, Killing SixLisbon Mayor Wants Companies to Help Fix City’s Housing ShortagePresident Donald Trump’s administration pressed forward with plans to impose tariffs on semiconductor and pharmaceutical imports by initiating trade",
    "url": "https://finnhub.io/api/news?id=795938dc3145a689055e139871037666a344686709a9ebbfb8180cb558a8c6b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744687957,
      "headline": "Trump Initiates Chips and Drug Probes Ahead of More Tariffs",
      "id": 133917679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergHow Did This Suburb Figure Out Mass Transit?The Secret Formula for Faster TrainsEven Oslo Has an Air Quality ProblemNYC Tourist Helicopter Crashes in Hudson River, Killing SixLisbon Mayor Wants Companies to Help Fix City’s Housing ShortagePresident Donald Trump’s administration pressed forward with plans to impose tariffs on semiconductor and pharmaceutical imports by initiating trade",
      "url": "https://finnhub.io/api/news?id=795938dc3145a689055e139871037666a344686709a9ebbfb8180cb558a8c6b7"
    }
  }
]